

# GRIFOLS

## CONFIDENTIAL SUSPECTED ADVERSE REACTION REPORT

### PATIENT INFORMATION

Patient initials: \_\_\_\_\_ Patient's medical record number: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Age: \_\_\_\_\_  
Sex:  Female  Male Weight (kg): \_\_\_\_\_ If female, is the patient pregnant?  No (the patient is not pregnant)  Yes (the patient is pregnant)  
Allergies: \_\_\_\_\_  
Medical history (medical conditions): \_\_\_\_\_  
\_\_\_\_\_

### SUSPECTED MEDICINE

Name & strength of the medicine: \_\_\_\_\_  
Batch number(s): \_\_\_\_\_  
Dosage & frequency prescribed: \_\_\_\_\_  
Amount received when the reaction occurred: \_\_\_\_\_  
Administration date: \_\_\_\_\_  
Infusion start & stop times: \_\_\_\_\_  
Route of administration & infusion rate: \_\_\_\_\_  
Reason for use (indication): \_\_\_\_\_  
Has the patient previously received this medicine?  No, first time  Yes If yes, please describe previous response: \_\_\_\_\_  
Has the patient previously had any IVIG medication?  No  Yes If yes, please describe previous response: \_\_\_\_\_

### INFORMATION ABOUT THE REACTION

Date of onset of the reaction: \_\_\_\_/\_\_\_\_/\_\_\_\_  
Where did the patient receive the infusion?  Outpatient services  Hospital (inpatient)  Other (specify): \_\_\_\_\_  
Description of the reaction: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Action taken:  Infusion discontinued  Infusion interrupted  Infusion rate reduced  None  Unknown

Did the adverse event(s) improve following discontinuation? \_\_\_\_\_

If the infusion was reintroduced, did the reaction(s) reappear after reintroduction? \_\_\_\_\_

#### Outcome:

- Recovered (date of recovery: \_\_\_\_/\_\_\_\_/\_\_\_\_)  
 Recovered with sequelae (specify sequelae: \_\_\_\_\_)  
 Recovering  
 Not recovered  
 Fatal  
 Unknown

#### Severity of the reaction:

- Mild  
 Moderate  
 Severe  
 Unknown

# GRIFOLS

## CONFIDENTIAL SUSPECTED ADVERSE REACTION REPORT

Please indicate the seriousness of the reaction(s) based on the following criteria (tick any/all that apply):

- Involved hospitalisation of longer than 24 hours in duration (admission date: \_\_\_\_/\_\_\_\_/\_\_\_\_ discharge date: \_\_\_\_/\_\_\_\_/\_\_\_\_)
- Lengthened an existing hospitalisation (the patient was already an inpatient prior to receiving the infusion and the patient's stay in hospital was lengthened because of the reaction)
- Considered medically significant (seriously jeopardised the patient)
- Resulted in persistent or significant disability or incapacity
- Was associated with a congenital anomaly or birth defect
- Was life threatening
- Resulted in death (date of death: \_\_\_\_/\_\_\_\_/\_\_\_\_ cause of death: \_\_\_\_\_)
- None of the above

Causality (likelihood the suspected medicine caused the events):

- Certain       Probable       Possible       Unlikely       Not related       Not assessable

### TREATMENT OF THE REACTION

Medicine:	Dose:	Date begun:	Date stopped:	Reason for use:
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____

Any other treatment: \_\_\_\_\_

### CONCOMITANT MEDICATIONS

Medicine:	Dose:	Reason for use:
_____	_____	_____
_____	_____	_____
_____	_____	_____

### REPORTER INFORMATION

Occupation:  Doctor  Nurse  Other (please specify) \_\_\_\_\_

Full Name: \_\_\_\_\_

Email: \_\_\_\_\_

Location (address): \_\_\_\_\_

Phone number: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Please email this completed report to:  
**australia\_medinfo@grifols.com**

Data Protection Information: For information about what we do with your personal data, please see our [privacy notice](http://www.grifols.com/en/privacy-notice) at [www.grifols.com/en/privacy-notice](http://www.grifols.com/en/privacy-notice)